Affinage

Showing BCL9L — BCL9-2 is a alias.

BCL9L

B-cell CLL/lymphoma 9-like protein · UniProt Q86UU0

Length
1499 aa
Mass
157.1 kDa
Annotated
2026-06-09
26 papers in source corpus 15 papers cited in narrative 15 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 8/9 claims corpus-supported (89%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

BCL9L (BCL9-2/B9L) is a nuclear transcriptional co-activator of the canonical Wnt pathway that potentiates β-catenin/TCF-driven transcription and governs developmental and oncogenic programs of epithelial-mesenchymal transition (EMT) and stem-cell maintenance (PMID:15371335, PMID:15574752, PMID:20682801). It engages the β-catenin/TCF complex to enhance its transactivation potential, an activity required for elevated Wnt-target gene expression and β-catenin-induced cellular transformation (PMID:15574752). Structure-function analysis defines two separable interaction modules: an HD2 domain that binds β-catenin and an HD1 domain that binds Pygopus, with the HD2-β-catenin interaction being the principal driver of tumor growth, invasion, and metastasis, while combined loss of Bcl9/Bcl9L causes tumor cell death (PMID:34545187). Functionally, BCL9L promotes the switch of β-catenin from adhesive (membrane, E-cadherin/α-catenin-associated) to transcriptional (nuclear) roles, and its depletion restores E-cadherin and membrane β-catenin, reverses EMT, and suppresses metastasis (PMID:15371335, PMID:27713160). In vivo, Bcl9/Bcl9L are required for Wnt-dependent intestinal stem-cell maintenance and a subset of EMT/stem-cell Wnt target genes, and BCL9-2 overexpression accelerates intestinal and mammary tumorigenesis (PMID:20682801, PMID:21703997, PMID:25149534). Beyond Wnt, BCL9L maintains basal caspase-2 levels to enable caspase-2-mediated cleavage of MDM2 and BID; its loss suppresses this axis and promotes tolerance of chromosomal missegregation and aneuploidy independent of TP53 (PMID:28073006). BCL9L also drives ERα (ESR1) expression in breast cancer through a β-catenin-independent interaction with Sp1 at the proximal ESR1 promoter (PMID:25149534). Its transcriptional activity is negatively regulated by nuclear WWOX, an inhibition enhanced by HDAC3 independent of deacetylase activity (PMID:25678599), and its expression is constrained by miR-22/miR-214 targeting and modulated by 3′UTR variation (PMID:30698996, PMID:35628130). Targeting the BCL9/β-catenin interaction additionally remodels the tumor immune microenvironment, enhancing cytotoxic T-cell and cDC1 infiltration (PMID:33767438, PMID:38811552).

Mechanistic history

Synthesis pass · year-by-year structured walk · 14 steps
  1. 2004 High

    Established BCL9L as a β-catenin partner that toggles β-catenin between adhesion and transcription, answering how a Wnt effector could drive EMT.

    Evidence RNAi knockdown and overexpression in carcinoma/nontransformed cells plus zebrafish Wnt8 epistasis

    PMID:15371335

    Open questions at the time
    • Mechanistic basis of the membrane-to-nuclear β-catenin switch not fully resolved
    • Role of Tyr142 phosphorylation later contested
  2. 2004 High

    Showed BCL9L is required for elevated β-catenin/TCF transcription and transformation, defining it as a bona fide co-activator in colorectal cancer.

    Evidence Co-IP, luciferase reporters, RNAi, and RK3E transformation assay

    PMID:15574752

    Open questions at the time
    • Domain architecture mediating the interaction not yet mapped
    • Target gene specificity unaddressed
  3. 2006 High

    Clarified that BCL9L co-activator function depends on Pygopus binding and refuted the requirement for β-catenin Tyr142 phosphorylation in recruitment and Wg signaling.

    Evidence Drosophila genetic complementation of lgs mutants, Tyr142 mutagenesis, and reporter assays

    PMID:17113272

    Open questions at the time
    • Reconciliation with the earlier Tyr142-based adhesion/transcription model left open
  4. 2010 High

    Demonstrated an in vivo requirement for Bcl9/Bcl9L in Wnt-driven intestinal stem-cell maintenance and a defined EMT/stem-cell target gene subset.

    Evidence Conditional Bcl9/Bcl9L knockout in mouse intestine with transcriptional profiling of adenocarcinomas

    PMID:20682801

    Open questions at the time
    • Which direct targets are regulated not resolved
    • Redundancy between Bcl9 and Bcl9L not dissected
  5. 2011 High

    Showed BCL9-2 controls both β-catenin-dependent and -independent targets and accelerates tumorigenesis, broadening its role beyond canonical Wnt output.

    Evidence siRNA in colon cancer cells and transgenic overexpression crossed to APCMin/+ mice

    PMID:21703997

    Open questions at the time
    • Identity and mechanism of β-catenin-independent targets unspecified
  6. 2014 Medium

    Identified a β-catenin-independent route by which BCL9-2 drives ERα expression via Sp1, linking it to ER-positive breast cancer.

    Evidence BCL9-2 transgenic mice, siRNA, ESR1 promoter-reporter and Sp1 interaction assays

    PMID:25149534

    Open questions at the time
    • Single-lab finding
    • Structural basis of BCL9L-Sp1 interaction unknown
  7. 2015 Medium

    Defined negative regulation of BCL9-2 transcriptional activity by WWOX, with HDAC3 enhancing this inhibition deacetylase-independently.

    Evidence Reciprocal Co-IP, luciferase reporters in MCF-7, Xenopus axis induction, colocalization microscopy

    PMID:25678599

    Open questions at the time
    • Single-lab study
    • How WWOX blocks β-catenin-TCF1 without disrupting BCL9-2/β-catenin not structurally resolved
  8. 2016 Medium

    Placed BCL9L upstream of EMT in pancreatic cancer by controlling β-catenin membrane-nuclear distribution and metastatic capacity.

    Evidence RNAi, E-cadherin/β-catenin Western blots, invasion assays, liver-metastasis xenografts

    PMID:27713160

    Open questions at the time
    • Single-lab study
    • Interplay with TGF-β signaling described but not mechanistically dissected
  9. 2017 High

    Uncovered a Wnt-independent function: BCL9L sustains basal caspase-2 to enable MDM2/BID cleavage, and its loss licenses aneuploidy tolerance independent of TP53.

    Evidence Colorectal cancer genomics, knockdown/deficiency, xenografts, caspase-2 and MDM2/BID cleavage assays

    PMID:28073006

    Open questions at the time
    • Direct mechanism by which BCL9L maintains caspase-2 levels unknown
    • Connection to its transcriptional role unclear
  10. 2019 Medium

    Showed a non-redundant, BCL9L-specific requirement for active Wnt transcription in hepatocellular carcinoma.

    Evidence siRNA, Wnt reporter, and viability/apoptosis assays in Wnt-active vs -inactive HCC lines

    PMID:31440992

    Open questions at the time
    • Weak single-method evidence
    • Basis of BCL9L vs BCL9 specificity not explained
  11. 2019 Medium

    Positioned BCL9L as a direct miR-22/miR-214 target whose suppression recapitulates anti-EMT, anti-proliferative effects in colon cancer.

    Evidence Dual-luciferase reporter validation, siRNA, miRNA overexpression and functional rescue

    PMID:30698996

    Open questions at the time
    • Single-lab study
    • In vivo relevance of miRNA regulation untested
  12. 2021 High

    Dissected the separable HD1-Pygopus and HD2-β-catenin modules in vivo, establishing HD2-β-catenin binding as the dominant driver of tumor growth and metastasis.

    Evidence MMTV-PyMT conditional knockout, HD1/HD2 deletions, β-catenin D164A point mutation, tumor/metastasis quantification

    PMID:34545187

    Open questions at the time
    • Why HD1-Pygopus contributes only moderately not resolved
    • Mechanism of cell death on complete knockout undefined
  13. 2021 Medium

    Extended BCL9/BCL9L function to immune evasion, showing pharmacological β-catenin disruption boosts cytotoxic T-cell infiltration and synergizes with checkpoint blockade.

    Evidence Genetic and pharmacological (hsBCL9CT-24) perturbation in TNBC models with immune infiltration and combination therapy

    PMID:33767438

    Open questions at the time
    • Pathway placement partly inferred
    • Distinction between Wnt and TGF-β contributions to immune phenotype unclear
  14. 2024 Medium

    Defined a mechanism for the immune phenotype: BCL9/BCL9L loss enhances cDC1 activation and antigen presentation via XCL1-XCR1 and NF-κB/IRF1 signaling.

    Evidence Bcl9/Bcl9l knockout mice, hsBCL9z96 inhibitor, single-cell transcriptomics, CD8+ T-cell quantification

    PMID:38811552

    Open questions at the time
    • Single-lab study
    • Whether the cDC1 effect is cell-intrinsic to BCL9L in dendritic cells fully established

Open questions

Synthesis pass · forward-looking unresolved questions
  • How BCL9L's Wnt-transcriptional, caspase-2/aneuploidy, ERα/Sp1, and immune-microenvironment functions are integrated within single tumors remains unresolved.
  • No unified model linking the distinct activities
  • Direct genomic targets of BCL9L not comprehensively mapped
  • Mechanism maintaining basal caspase-2 unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 3 GO:0060090 molecular adaptor activity 2
Localization
GO:0005634 nucleus 2
Pathway
R-HSA-162582 Signal Transduction 3 R-HSA-1643685 Disease 2 R-HSA-168256 Immune System 2 R-HSA-74160 Gene expression (Transcription) 2 R-HSA-1266738 Developmental Biology 1
Partners
CTNNB1HDAC3PYGOSP1WWOX
Complex memberships
β-catenin/TCF transcriptional complex

Evidence

Reading pass · 15 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2004 BCL9-2 (BCL9L) binds β-catenin and promotes a switch from adhesive to transcriptional functions: phosphorylation of Tyr142 of β-catenin favors BCL9-2 binding and precludes interaction with α-catenin, thereby promoting nuclear β-catenin-dependent transcription and epithelial-mesenchymal transition. RNA interference knockdown in carcinoma cells (inducing epithelial phenotype and membrane translocation of β-catenin), overexpression in nontransformed cells (inducing EMT), genetic epistasis in zebrafish embryogenesis placing BCL9-2 in the Wnt8-signaling pathway Genes & development High 15371335
2004 BCL9L (B9L) interacts with the β-catenin-TCF complex and enhances its transactivation potential; B9L is required for elevated β-catenin-TCF-mediated transcription in colorectal tumor cells and for β-catenin-induced cellular transformation. Co-immunoprecipitation, luciferase reporter transcription assays, RNAi knockdown in colorectal tumor cells, RK3E transformation assay Cancer research High 15574752
2006 BCL9-2 can functionally replace Drosophila Legless (Lgs) in Wnt/Wg signaling both in cultured mammalian cells and in vivo in Drosophila, and this rescue activity depends on BCL9-2's ability to bind Pygopus; Tyr142 phosphorylation of β-catenin/Armadillo is NOT required for BCL9-2 recruitment, nor for transcriptional activity of β-catenin in cultured cells or Wg signaling in vivo. Genetic complementation (BCL9-2 rescue of lgs mutants in Drosophila), luciferase reporter assays in cultured mammalian cells, mutagenesis of Tyr142, in vivo Drosophila Wg signaling assays Mechanisms of development High 17113272
2010 Bcl9/Bcl9l are required in the intestinal epithelium for Wnt-mediated stem cell maintenance and regulation of a subset of Wnt target genes involved in EMT and stem cell properties; conditional ablation reduces stem cell markers and impairs colon epithelium regeneration, and abrogates EMT/stem cell gene expression signatures in adenocarcinomas. Conditional knockout of Bcl9/Bcl9l in mouse intestinal epithelium, transcriptional profiling of adenocarcinomas from wild-type vs. mutant mice Cancer research High 20682801
2011 BCL9-2 regulates expression of both β-catenin-dependent and β-catenin-independent target genes in intestinal tumorigenesis; transgenic overexpression of BCL9-2 in APCMin/+ mice accelerated adenoma formation and progression to invasive tumors, and siRNA analysis showed BCL9s and Pygopus are not themselves Wnt target genes in colon cancer cells. siRNA knockdown in colon cancer cells, transgenic mouse overexpression crossed with APCMin/+ model, specific antibody characterization Gastroenterology High 21703997
2015 WWOX interacts with BCL9-2 and inhibits its transcriptional activity in the Wnt/β-catenin pathway; HDAC3 associates with BCL9-2, promotes the WWOX-BCL9-2 interaction independent of its deacetylase activity, and enhances WWOX-mediated inhibition of BCL9-2 transcriptional activity. WWOX inhibits the β-catenin-TCF1 interaction but does not disrupt BCL9-2/β-catenin association. Co-immunoprecipitation, luciferase reporter assays in MCF-7 cells, Xenopus secondary axis induction assay, colocalization by microscopy Molecular cancer research Medium 25678599
2014 BCL9-2 regulates estrogen receptor alpha (ERα) expression in breast cancer cells through a β-catenin-independent mechanism involving interaction with Sp1 at the proximal ESR1 gene promoter; BCL9-2 transgenic mice develop ER-positive ductal mammary tumors. BCL9-2 transgenic mouse model, siRNA knockdown in breast cancer cells, promoter-reporter assay, interaction with Sp1 demonstrated Oncotarget Medium 25149534
2017 BCL9L dysfunction (loss of heterozygosity/mutation) reduces basal caspase-2 levels and prevents cleavage of MDM2 and BID, thereby promoting tolerance of chromosomal missegregation and aneuploidy in colorectal cancer cells, independent of TP53 status. Genomic analysis of colorectal cancers, BCL9L knockdown/deficiency in cell lines, xenograft models, measurement of caspase-2 levels, MDM2 and BID cleavage assays Cancer cell High 28073006
2016 BCL9L depletion in pancreatic cancer cells causes increased E-cadherin levels, membrane retention of β-catenin, adoption of an epithelial phenotype even in the presence of TGF-β, and significantly reduces liver metastases in xenograft models, placing BCL9L upstream of EMT regulation through β-catenin membrane-nuclear distribution. RNAi knockdown, Western blotting for E-cadherin/β-catenin, migration/invasion assays, xenograft mouse model Oncotarget Medium 27713160
2021 The interactions of Bcl9/Bcl9L with β-catenin (via HD2 domain) and with Pygopus (via HD1 domain) are mechanistically separable: disrupting HD2-mediated β-catenin binding diminishes primary tumor growth, cell proliferation, invasion, and lung metastasis in the MMTV-PyMT breast cancer mouse model, while disrupting HD1-Pygopus interaction has only moderate effects. Complete knockout of both Bcl9/Bcl9L results in tumor cell death. Conditional knockout in MMTV-PyMT transgenic mice, domain deletion (HD1 or HD2), point mutation in β-catenin (D164A), tumor growth and metastasis quantification Oncogene High 34545187
2021 BCL9/BCL9L promotes tumorigenicity through both Wnt and TGF-β signaling pathways, and BCL9/BCL9L inhibits CD8+ T cell infiltration into the tumor microenvironment; pharmacological inhibition of BCL9/β-catenin interaction with hsBCL9CT-24 promotes cytotoxic T cell infiltration and reduces regulatory T cells, synergizing with PD-1/L1 antibodies. Genetic knockdown/knockout, pharmacological inhibitor (hsBCL9CT-24) in TNBC models, immune cell infiltration analysis, combination therapy experiments Oncogene Medium 33767438
2024 Targeting BCL9/BCL9L (by pharmacological inhibition with hsBCL9z96 or Bcl9/Bcl9l knockout) promotes antigen presentation in tumors by enhancing cDC1 activation and tumor infiltration via the XCL1-XCR1 axis; Bcl9/Bcl9l-deficient cDC1 show superior activation and antigen presentation through NF-κB/IRF1 signaling. Bcl9/Bcl9l knockout mice, pharmacological inhibitor (hsBCL9z96), single-cell transcriptomics, tumor growth assays, CD8+ T cell response quantification Signal transduction and targeted therapy Medium 38811552
2019 Knockdown of BCL9L (but not BCL9) reduces Wnt signaling reporter activity in Wnt-active hepatocellular carcinoma cells (HepG2, Huh6), demonstrating a non-redundant role of BCL9L specifically in maintaining active Wnt/β-catenin transcription in these cells. siRNA knockdown, Wnt reporter assay, cell viability/apoptosis assays in Wnt-active vs Wnt-inactive HCC cell lines Hepatology international Medium 31440992
2019 BCL9L is a direct target of both miR-22 and miR-214 in colon cancer, as validated by dual-luciferase reporter assay; BCL9L knockdown phenocopies miR-22/miR-214 overexpression in suppressing proliferation, migration, and EMT marker changes (increased E-cadherin, decreased vimentin). Dual-luciferase reporter assay, siRNA knockdown, miRNA overexpression, cell proliferation and migration assays FASEB journal Medium 30698996
2022 A 3′ UTR A>T mutation in BCL9L reduces its mRNA expression and luciferase reporter activity in bladder cancer cells; BCL9L knockdown represses proliferation, migration, and invasion, and reduces Wnt/β-catenin target gene mRNA levels in Cal29 cells (but not T24 cells, indicating cell-line-specific dependence). Luciferase reporter assay for UTR mutations, siRNA knockdown, proliferation/migration/invasion assays (xCelligence), RT-qPCR for Wnt target genes International journal of molecular sciences Medium 35628130

Source papers

Stage 0 corpus · 26 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2004 Essential role of BCL9-2 in the switch between beta-catenin's adhesive and transcriptional functions. Genes & development 273 15371335
2003 Identification and characterization of human BCL9L gene and mouse Bcl9l gene in silico. International journal of molecular medicine 114 12964048
2010 Bcl9/Bcl9l are critical for Wnt-mediated regulation of stem cell traits in colon epithelium and adenocarcinomas. Cancer research 109 20682801
2004 Role of a BCL9-related beta-catenin-binding protein, B9L, in tumorigenesis induced by aberrant activation of Wnt signaling. Cancer research 79 15574752
2017 BCL9L Dysfunction Impairs Caspase-2 Expression Permitting Aneuploidy Tolerance in Colorectal Cancer. Cancer cell 77 28073006
2021 Long non-coding RNA LINC00665 promotes gemcitabine resistance of Cholangiocarcinoma cells via regulating EMT and stemness properties through miR-424-5p/BCL9L axis. Cell death & disease 49 33436545
2011 BCL9-2 promotes early stages of intestinal tumor progression. Gastroenterology 47 21703997
2021 Matrix stiffness promotes glioma cell stemness by activating BCL9L/Wnt/β-catenin signaling. Aging 38 33535177
2021 BCL9/BCL9L promotes tumorigenicity through immune-dependent and independent mechanisms in triple negative breast cancer. Oncogene 35 33767438
2006 BCL9-2 binds Arm/beta-catenin in a Tyr142-independent manner and requires Pygopus for its function in Wg/Wnt signaling. Mechanisms of development 32 17113272
2019 Wnt status-dependent oncogenic role of BCL9 and BCL9L in hepatocellular carcinoma. Hepatology international 30 31440992
2016 Role of BCL9L in transforming growth factor-β (TGF-β)-induced epithelial-to-mesenchymal-transition (EMT) and metastasis of pancreatic cancer. Oncotarget 26 27713160
2019 miR-22 and miR-214 targeting BCL9L inhibit proliferation, metastasis, and epithelial-mesenchymal transition by down-regulating Wnt signaling in colon cancer. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 25 30698996
2021 The interactions of Bcl9/Bcl9L with β-catenin and Pygopus promote breast cancer growth, invasion, and metastasis. Oncogene 24 34545187
2024 Targeting BCL9/BCL9L enhances antigen presentation by promoting conventional type 1 dendritic cell (cDC1) activation and tumor infiltration. Signal transduction and targeted therapy 20 38811552
2020 miR-766-3p Targeting BCL9L Suppressed Tumorigenesis, Epithelial-Mesenchymal Transition, and Metastasis Through the β-Catenin Signaling Pathway in Osteosarcoma Cells. Frontiers in cell and developmental biology 19 33117820
2014 The BCL9-2 proto-oncogene governs estrogen receptor alpha expression in breast tumorigenesis. Oncotarget 19 25149534
2016 BCL9L expression in pancreatic neoplasia with a focus on SPN: a possible explanation for the enigma of the benign neoplasia. BMC cancer 16 27539223
2007 Immunohistochemical expression of the beta-catenin-interacting protein B9L is associated with histological high nuclear grade and immunohistochemical ErbB2/HER-2 expression in breast cancers. Cancer science 16 17309600
2022 Wnt/β-Catenin Signalling and Its Cofactor BCL9L Have an Oncogenic Effect in Bladder Cancer Cells. International journal of molecular sciences 15 35628130
2021 Type I collagen promotes tumor progression of integrin β1 positive gastric cancer through a BCL9L/β-catenin signaling pathway. Aging 15 34319913
2007 Up-regulation of a BCL9-related beta-catenin-binding protein, B9L, in different stages of sporadic colorectal adenoma. Cancer science 15 17129358
2005 Identification and characterization of rat Bcl9l gene in silico. International journal of oncology 15 15703843
2015 The Tumor-Suppressor WWOX and HDAC3 Inhibit the Transcriptional Activity of the β-Catenin Coactivator BCL9-2 in Breast Cancer Cells. Molecular cancer research : MCR 13 25678599
2023 Corrigendum: miR-766-3p targeting BCL9L suppressed tumorigenesis, epithelial-mesenchymal transition, and metastasis through the β-catenin signaling pathway in osteosarcoma cells. Frontiers in cell and developmental biology 1 38033858
2026 CD44/POU2F2/BCL9L axis mediates MIF-driven SPP1+TAM activation in colorectal cancer metastasis. International journal of biological sciences 0 41800265

Missed literature

Know a paper Affinage missed for BCL9L? Flag it for the maintainers and the community.

No submissions yet.